Nezulcitinib
Modify Date: 2024-01-19 09:30:24
Nezulcitinib structure
|
Common Name | Nezulcitinib | ||
|---|---|---|---|---|
| CAS Number | 2412496-23-0 | Molecular Weight | 527.66 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C30H37N7O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of NezulcitinibNezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (JAK) inhibitor. Nezulcitinib can be used for the research of COVID-19 associated acute lung injury and impaired oxygenation[1][2]. |
| Name | Nezulcitinib |
|---|
| Description | Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (JAK) inhibitor. Nezulcitinib can be used for the research of COVID-19 associated acute lung injury and impaired oxygenation[1][2]. |
|---|---|
| Related Catalog | |
| Target |
JAK |
| In Vitro | Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (JAK) inhibitor[1][2]. |
| References |
[1]. Theravance's nezulcitinib fails to meet Phase II goals in Covid-19 |
| Molecular Formula | C30H37N7O2 |
|---|---|
| Molecular Weight | 527.66 |